The good and the bad faces of STAT1 in solid tumours

详细信息    查看全文

• 作者：Katrin Meissl¹ ; Sabine Macho-Maschler¹ ; Mathias Mü ; ller ; Birgit Strobl ; ^{birgit.strobl@vetmeduni.ac.at}
• 关键词：BAD ; Bcl2-associated agonist of cell death ; Bcl ; B-cell lymphoma ; CD ; cluster of differentiation ; CDK ; cyclin-dependent kinase ; CTL ; cytotoxic T lymphocyte ; CUG ; cancer upregulated gene ; CXCL ; C-X-C motive ligand ; DC ; dendritic cells ; DAMP ; danger-associated molecular pattern ; DR ; death receptor ; ER ; estrogen receptor ; ERBB2/neu ; Erb-B2 receptor tyrosine Kinase 2 ; ERK ; extracellular signal-regulated kinase ; FASL ; FAS ligand ; FADD ; Fas-associated protein with death domain ; FGF ; fibroblast growth
• 刊名：Cytokine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：89
• 期：Complete
• 页码：12-20
• 全文大小：856 K
• 卷排序：89

文摘

Signal transducer and activator of transcription (STAT) 1 is part of the Janus kinase (JAK)/STAT signalling cascade and is best known for its essential role in mediating responses to all types of interferons (IFN). STAT1 regulates a variety of cellular processes, such as antimicrobial activities, cell proliferation and cell death. It exerts important immune modulatory activities both in the innate and the adaptive arm of the immune system. Based on studies in mice and data from human patients, STAT1 is generally considered a tumour suppressor but there is growing evidence that it can also act as a tumour promoter. This review aims at contrasting the two faces of STAT1 in tumourigenesis and providing an overview on the current knowledge of the underlying mechanisms or pathways.